Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,600.00
Bid: 1,598.00
Ask: 1,598.50
Change: -4.50 (-0.28%)
Spread: 0.50 (0.031%)
Open: 1,613.00
High: 1,613.00
Low: 1,589.00
Prev. Close: 1,604.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US STOCKS-Futures point to flat open despite some strong earnings

Tue, 22nd Apr 2014 12:59

* S&P 500, Nasdaq coming off five-day advances

* Netflix jumps, results show strong subscriber growth

* Travelers and United Tech profits top expectations

* Futures up: Dow 6 pts, S&P 0.7 pt, Nasdaq 2.25 pts (Adds McDonald's results)

By Ryan Vlastelica

NEW YORK, April 22 (Reuters) - U.S. stock index futurespointed to a flat open on Tuesday as investors found few reasonsto keep buying after a five-day rally in the S&P 500, despitestrong results from a number of bellwether names.

* Netflix Inc surged 7.8 percent to $375.74 inpremarket trading a day after results showed strong subscribergrowth, a sign that the trading favorite still had room to growdespite concerns over its elevated valuation.

* Dow components Travelers Cos Inc and UnitedTechnologies Corp both reported first-quarter earningsthat beat expectations, and United Tech raised the low end ofits full-year profit outlook. Shares of Travelers rose 0.4percent to $86.75 before the bell.

* The three were the latest prominent names to topforecasts, continuing a trend that last week helped lift the S&P500 to its best week since July. McDonald's Corp reported earnings that fell alongside a drop in U.S. same-storesales, though the Dow component rose 0.9 percent to $100.60before the bell.

* Dozens of S&P 500 components are slated to report thisweek. Of the 87 that had reported thus far, 62.1 percent havetopped earnings expectations, according to Thomson Reuters data,compared with the 66 percent average over the past fourquarters. On revenue, 51.7 percent have exceeded forecasts,below the 54 percent average over the past four quarters.

* S&P 500 companies' first-quarter earnings are projected tohave increased 0.8 percent from a year ago, Thomson Reuters datashowed. The forecast is down sharply from the start of the year,when profit growth was estimated at 6.5 percent.

* S&P 500 futures rose 0.7 point and were slightlyunder fair value, a formula that evaluates pricing by takinginto account interest rates, dividends and time to expiration onthe contract. Dow Jones industrial average futures added6 points and Nasdaq 100 futures rose 2.25 points.

* European shares were sharply higher on the day,rising 1.1 percent on the back of deal activity in thepharmaceutical space, including Novartis both swappingassets with GlaxoSmithKline and selling a unit to EliLilly & Co. U.S. shares of Glaxo rose 4 percent to$55.23 in premarket trading.

* In company news, Allergan Inc jumped 17.5 percentto $166.75 in premarket trading a day after activist investorWilliam Ackman teamed up with Canadian drugmaker ValeantPharmaceuticals International Inc to make a joint bidfor the company.

* General Motors Co filed a motion in a U.S.bankruptcy court to enforce a bar on lawsuits related toignition defects in cars sold before its 2009 bankruptcy as itfights a class action lawsuit that seeks to set aside therestriction. (Editing by Chizu Nomiyama and Nick Zieminski)

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.